bioRxiv ScienceSearch

bioRxiv · 10.1101/308486

iPSC-derived neurons as a tool for probing molecular pharmacology of antipsychotic action.

Abstract

BackgroundInduced pluripotent stem cell derived neurons (iPSC-Neurons) provide a potential way to investigate molecular mechanisms of psychotropic drug action in human neurons. Until now such studies have relied on animal models or artificial expression systems in transfected cells.\n\nMethodsInduced pluripotent stem cells were subjected to a dual SMAD inhibition differentiation protocol. Resulting neurons were examined using qPCR, immunocytochemistry, viral transduction, and calcium imaging.\n\nResultsHere we report the presence of target receptors for antipsychotic drugs in human iPSC-neurons. A cortical neuronal differentiation protocol resulted in cells that expressed D2, 5HT2A, and other target receptors. Moreover, stimulation with glutamate, dopamine, or the 5HT2A agonist DOI evoked calcium transients. We analyzed single cell responses, and found cells with signature response profiles to these ligands. In addition, pre-incubation of iPSC-neurons with clozapine altered the proportion of cells that responded to glutamate or DOI in a subpopulation of neurons.\n\nConclusionsOur results support the use of iPSC-neuron single cell pharmacology for studying how psychotropic medications modulate neuronal responses. Because these cells can be derived directly from patients, results derived from using iPSC-neurons have immediate relevance for personalized medicine.\n\nSignificance StatementThe current study examines the feasibility of using induced pluripotent stem cells from patients to generate neurons and study psychopharmacology. This article is broadly intended to inform the readership on the key points of iPSC-derived neurons as a system and how it can be used to understand antipsychotic pharmacology for potential clinical application. The specific advances include 1) demonstrating the presence of receptors targeted by antipsychotics on iPSC-derived neurons; 2) Using single cell analysis to identify human neurons with distinct responses to receptor modulation; and 3) Demonstrating that clozapine modulates glutamatergic and serotonergic responses in distinct human neuronal populations.

Explore related subjects

Keep this discovery

BibTeXRIS

Kim, E. S., Leonardo, E. D., Dranovsky, A.. 2018-04-25. iPSC-derived neurons as a tool for probing molecular pharmacology of antipsychotic action.. https://doi.org/10.1101/308486

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Lipid-ASO therapeutics exhibit differential tissue targeted delivery upon systemic or local CNS administration

Antisense oligonucleotides (ASOs) are a powerful therapeutic modality, but their full potential is hindered by pharmacokinetic properties that affect tissue and cellular delivery. Lipid conjugation is increasingly used to modulate ASO's biodistribution and promote extrahepatic activity, yet lipid dependent effects on in vivo functional delivery, particularly in the central nervous system (CNS), remain less explored. Here, we performed a side by side in vivo comparison of cholesterol, palmitic acid (C16:0), docosanoic acid (C22:0), and eicosapentaenoic acid (C20:5) conjugated to a fully phosphorothioated 3 10 3 LNA gapmer ASO targeting the Malat1 long non coding RNA. Lipid-ASO conjugates were administered systemically or locally in the brain of mice and evaluated for tissue level and cellular level distribution by imaging, qPCR and single-cell RNA sequencing, simultaneously annotating cell origin and global transcriptional changes within the cell. Following systemic administration in mice, lipid conjugation improved overall multi organ efficacy compared to unconjugated ASO, but with pronounced tissue specific differences. Single cell sequencing of liver and heart transcriptomes revealed lipid dependent cellular uptake patterns and transcriptional responses distinct from administration of unconjugated ASO. After intracerebroventricular administration, selected fatty acid conjugates enhanced silencing in deep brain regions such as the striatum, whereas cholesterol conjugation impaired functional delivery despite increased CNS retention. Light-sheet microscopy showed restricted parenchymal penetration of cholesterol ASOs compared with broader but heterogeneous distribution of palmitic acid conjugate. Together, these findings demonstrate that lipid identity critically determines ASO efficacy, productive cellular uptake, and regional CNS engagement, emphasizing the need for context specific lipid design in ASO therapeutic development.

pharmacology and toxicology

Novel Dissymmetric Ionizable Lipid-Assembled Lipid Nanoparticles for Delivery of Ferroptosis-Related siRNA in Diabetic Treatment

Small interfering RNA (siRNA) enables precise post-transcriptional gene silencing for refractory diseases, yet its clinical translation remains limited by the lack of safe and efficient delivery vectors. Inspired by the dissymmetric alkyl chain architecture of natural membrane phospholipids, we designed and synthesized 34 novel ionizable lipids with dissymmetric hydrophobic tails and formulated them into lipid nanoparticles (LNPs). Through systematic physicochemical and biological assessments, we established clear structure-activity relationships and identified two lead LNPs (O14-LNP, H18a-LNP) with superior endosomal escape capacity, enhanced in vivo gene silencing potency, and favorable biosafety relative to the clinical benchmark MC3-LNP. In both streptozotocin-induced and spontaneous db/db type 2 diabetes (T2D) mouse models, lead LNPs delivering ferroptosis-related siRNAs effectively ameliorated glucose and lipid metabolic disorders, restored islet function, and alleviated hepatic steatosis. This study not only lays a theoretical foundation for the rational design of novel ionizable lipids, but also validates the therapeutic potential of siRNA therapy targeting ferroptosis, providing a versatile delivery platform and targeted therapeutic strategy for the treatment of T2D.

pharmacology and toxicology

Characterization of BSN175: A Drug to Treat Prader-Willi Syndrome

The purpose of this research is to choose the best analytical method for determining stability of BSN175. This research uses an accelerated stability study to compare the decomposed and stable drug using IR and 1H NMR spectroscopy. The Bootstrap Error-adjusted Single-sample Technique (BEST) was used to compare the effectiveness of these analytical methods and choose the best option for determining stability.

pharmacology and toxicology